p21Cip1 restrains pituitary tumor growth

As commonly encountered, pituitary adenomas are invariably benign. We therefore studied protective pituitary proliferative mechanisms. Pituitary tumor transforming gene (Pttg) deletion results in pituitary p21 induction and abrogates tumor development in Rb+/−Pttg−/− mice. p21 disruption restores attenuated Rb+/−Pttg−/− pituitary proliferation rates and enables high penetrance of pituitary, but not thyroid, tumor growth in triple mutant animals (88% of Rb+/− and 72% of Rb+/−Pttg−/−p21−/− vs. 30% of Rb+/−Pttg−/− mice developed pituitary tumors, P < 0.001). p21 deletion also accelerated S-phase entry and enhanced transformation rates in triple mutant MEFs. Intranuclear p21 accumulates in Pttg-null aneuploid GH-secreting cells, and GH3 rat pituitary tumor cells overexpressing PTTG also exhibited increased levels of mRNA for both p21 (18-fold, P < 0.01) and ATM (9-fold, P < 0.01). PTTG is abundantly expressed in human pituitary tumors, and in 23 of 26 GH-producing pituitary adenomas with high PTTG levels, senescence was evidenced by increased p21 and SA-β-galactosidase. Thus, either deletion or overexpression of Pttg promotes pituitary cell aneuploidy and p53/p21-dependent senescence, particularly in GH-secreting cells. Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas.

[1]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[2]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[3]  S. Shalet,et al.  Hypopituitarism following radiotherapy , 2008, Pituitary.

[4]  A. Bartke,et al.  Age-related alterations in pituitary and testicular functions in long-lived growth hormone receptor gene-disrupted mice. , 2007, Endocrinology.

[5]  K. Kovacs,et al.  Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. , 2007, Cancer research.

[6]  C. Méndez-Vidal,et al.  Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin , 2007, Cell Death and Differentiation.

[7]  F. Holsboer,et al.  RSUME, a Small RWD-Containing Protein, Enhances SUMO Conjugation and Stabilizes HIF-1α during Hypoxia , 2007, Cell.

[8]  S. Melmed,et al.  Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. , 2007, American journal of physiology. Cell physiology.

[9]  Jing Zhao,et al.  Activation of p53 by MEG3 Non-coding RNA* , 2007, Journal of Biological Chemistry.

[10]  S. Melmed,et al.  Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition , 2007, Oncogene.

[11]  S. Melmed,et al.  Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. , 2007, Endocrine reviews.

[12]  J. Franklyn,et al.  Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. , 2006, Carcinogenesis.

[13]  Z. Ju,et al.  p21 delays tumor onset by preservation of chromosomal stability , 2006, Proceedings of the National Academy of Sciences.

[14]  J. Hoeijmakers,et al.  A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis , 2006, Nature.

[15]  A. Lania,et al.  Mechanisms of Disease: mutations of G proteins and G-protein-coupled receptors in endocrine diseases , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[16]  D. Peeper,et al.  Oncogene-induced cell senescence--halting on the road to cancer. , 2006, The New England journal of medicine.

[17]  W. Farrell,et al.  Pituitary tumours: findings from whole genome analyses. , 2006, Endocrine-related cancer.

[18]  B. Scheithauer,et al.  Pathobiology of Pituitary Adenomas and Carcinomas , 2006, Neurosurgery.

[19]  C. Croce,et al.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. , 2006, Cancer cell.

[20]  S. Asa,et al.  Mechanisms of Disease: the pathogenesis of pituitary tumors , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[21]  D. Peeper,et al.  KLF4, p21 and context-dependent opposing forces in cancer , 2006, Nature Reviews Cancer.

[22]  H. Heng,et al.  ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. , 2005, Cancer research.

[23]  C. Capella,et al.  Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas. , 2005, Analytical and quantitative cytology and histology.

[24]  K. McManus,et al.  ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. , 2005, Molecular biology of the cell.

[25]  K. Kovacs,et al.  Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. , 2005, Molecular endocrinology.

[26]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[27]  J. Franklyn,et al.  Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells , 2005, Oncogene.

[28]  S. Melmed,et al.  Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. , 2005, Molecular endocrinology.

[29]  Jiri Bartek,et al.  Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.

[30]  J. Barrett,et al.  Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks , 2004, Nature Cell Biology.

[31]  R. DePinho,et al.  Telomeres, stem cells, senescence, and cancer. , 2004, The Journal of clinical investigation.

[32]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[33]  Jiandong Chen,et al.  Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. , 2003, Endocrinology.

[34]  K. Kovacs,et al.  Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Augusto Silva,et al.  Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis , 2002, Nature Genetics.

[36]  S. Melmed,et al.  Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. , 2001, Molecular endocrinology.

[37]  M. Serrano,et al.  Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. , 2001, Cancer research.

[38]  J. A. Bernal,et al.  Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. , 2001, Nucleic acids research.

[39]  M. Datto,et al.  RB regulates transcription of the p21/WAF1/CIP1 gene , 2001, Oncogene.

[40]  K. Kovacs,et al.  Reversible Transdifferentiation: Interconversion of Somatotrophs and Lactotrophs in Pituitary Hyperplasia , 2001, Modern Pathology.

[41]  Jiandong Chen,et al.  Pituitary Tumor Transforming Gene Causes Aneuploidy and p53-dependent and p53-independent Apoptosis* , 2000, The Journal of Biological Chemistry.

[42]  S. Nicosia,et al.  Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model , 2000, Oncogene.

[43]  D. Kurz,et al.  Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. , 2000, Journal of cell science.

[44]  S. Melmed,et al.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.

[45]  M. Vooijs,et al.  Developmental defects and tumor predisposition in Rb mutant mice , 1999, Oncogene.

[46]  M. Kirschner,et al.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.

[47]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[48]  Y Taya,et al.  Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Gartel,et al.  The growth-regulatory role of p21 (WAF1/CIP1). , 1998, Progress in molecular and subcellular biology.

[50]  S. Melmed,et al.  Isolation and characterization of a pituitary tumor-transforming gene (PTTG). , 1997, Molecular endocrinology.

[51]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[53]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.